An FDA advisory committee on Friday (Oct. 12) determined that the benefits of a proposed new sufentanil sublingual tablet support the product's approval, overriding three panel members who disagreed. The tablet, a drug-device combination that is five to 10 times more potent than fentanyl, is the first product proposed for acute pain severe enough to require an opioid analgesic, according to a memo FDA sent to its advisory committee members in September. FDA had rejected the product a year ago,...